AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KOCT 262 min read$NAUT

Nautilus Biotechnology Reports Third Quarter 2026 Financial Results

Nautilus Biotechnology, Inc. (NAUT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Nautilus Biotechnology Reports Third Quarter 2026 Financial Results SEATTLE, WA, October 27, 2026 – Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third quarter

Original reporting
SEC EDGAR 8-K
Published Oct 26, 2026, 10:46 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 10:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$NAUT
Bearish
high confidence
Mentioned
$NAUT
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$NAUTBearishLow
01

Why it matters

The Q3 results underscore early‑stage revenue generation and significant operating expenses, emphasizing the need for additional funding.

02

Market read

The filing provides the first public financial snapshot for NAUT, likely prompting short‑term price weakness while offering a glimpse of long‑term platform potential.

03

What to watch

Upcoming conference call may provide more detail on cash runway and future financing plans.

Relevance 7/10Novelty 6/10Timing: pre‑market today

Background

Nautilus Biotechnology develops a single‑molecule proteome analysis platform and recently published a Nature Methods paper and presented oncology assay data.

Company-level read

Ticker impact

$NAUTBearishHigh confidence
Context

Nautilus Biotechnology filed an 8‑K reporting Q3 2026 results, including $0.2M revenue, $15.6M net loss and a $6M ARPA‑H grant opportunity.

Expected impact

likely downward pressure as investors digest the loss and modest revenue

Evidence & confidence

First‑time disclosure of the quarter's financials for a development‑stage biotech; loss magnitude relative to cash runway signals near‑term dilution risk.

Market effects

Sector

Highlights funding challenges for early‑stage proteomics firms and may affect sentiment toward similar biotech stocks.

Regional

Limited to US biotech investors; no broader regional effect.

Global

Minimal global impact beyond niche biotech community.

Counterpoint

What could challenge this read

If the ARPA‑H grant materializes, the long‑term platform potential could outweigh short‑term loss concerns.

Key entities

  • company
    Nautilus Biotechnology, Inc.

    Development‑stage life sciences company reporting Q3 2026 results.

  • government_program
    ARPA‑H

    Funding source for a four‑year research consortium offering up to $6M.

Read at source← All news

Related articles

JUL 27
$NAUTMed

Nautilus Biotechnology Reports Second Quarter 2026 Financial Results

Nautilus Biotechnology, Inc. (NAUT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-q2268xkearnings.htm EX-99.1 Document Exhibit 99.1 Nautilus Biotechnology Reports Second Quarter 2026 Financial Results SEATTLE, WA, July 28, 2026 – Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform,

SEC EDGAR 8-K6 min
OCT 27
$VFCHigh

VF Corporation faces earnings test as Vans turnaround hangs in balance

VF Corporation (VFC) reports Q2 2027 earnings on Wednesday, with investors focused on the Vans brand's recovery. The company expects $0.53 EPS on $2.66B revenue, a turnaround from last quarter's loss. Analysts expect a 5% revenue decline but watch for signs of sequential improvement and guidance updates. VFC's stock has risen 30% from September lows, with a consensus price target of $18.96.

investing.com2 min
OCT 27
$HLTHighAI 8/10

Hilton Worldwide 3Q 2026: Revenue $3.33B, EPS $2.37— 10-Q Summary

Hilton Worldwide reported 3Q 2026 revenue of $3.33B, up 6.6% YoY, and net income of $536M, up 27.6% YoY. EPS was $2.37. The company opened 520 hotels and added 55,500 net rooms in the first nine months. Systemwide RevPAR rose 5.8%, with U.S. RevPAR up 7.0% and Europe up 6.5%. Hilton Honors membership grew 15% YoY to 270 million. The company noted potential delays in hotel openings due to inflation and interest rates.

tradingview.com1 min
OCT 27
$WHRMed

Builders Are Slashing Prices at a Record Pace as the Housing Market Freezes

Home builders' sentiment hit a 14-year low in October, with 43% cutting prices. Whirlpool (WHR) reported weak Q3 earnings, with shares falling 8.77% after hours. Builders like D.R. Horton (DHI) and Lennar (LEN) also saw stock declines. Pending home sales dropped 11.3% year-over-year, and mortgage rates averaged 7.32%. Whirlpool cut its 2026 sales and profit forecasts, citing soft demand.

247wallst.com3 min